L-Glutamine 관련 Irritable Bowel Syndrome (IBS)
CPilot RCTs suggest glutamine (5 g TID) reduces intestinal permeability and IBS-D symptoms in post-infectious IBS. Promising but needs larger trials.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dl\u002Dglutamine\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
결론
Pilot RCTs suggest glutamine (5 g TID) reduces intestinal permeability and IBS-D symptoms in post-infectious IBS. Promising but needs larger trials.
Key Study Findings
Other
Unraveling the active ingredients and molecular mechanisms of Qinghua Changyan granule against irritable bowel syndrome …
Dose: None
vs: None
Outcome: IBS-D symptom relief via gut microbiota and glutamine …
효과: None
None
대상 집단: animal model of IBS with diarrhea
Other
n=25
4 weeks
Effect of probiotic administration of Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917 …
Dose: Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917
vs: phosphate-buffered saline (PBS)
Outcome: visceral hypersensitivity (abdominal withdrawal reflex scores)
효과: None
p<0.05
대상 집단: female rats with water avoidance stress-induced IBS-D model
Other
n=62
[Study on activation mechanism of SGCs in representation along the distribution of stomach meridian in …
Dose: None
vs: Control group (no citrobacter)
Outcome: SGC activation in DRG segments
효과: None
P<0.05 to P<0.01
대상 집단: Male C57BL/6 mice (IBS-D model)
Review
Intestinal Barrier Impairment, Preservation, and Repair: An Update.
Dose: None
vs: None
Outcome: Intestinal barrier preservation and repair
효과: None
None
대상 집단: IBD and IBS patients (review)
Other
Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes.
Dose: None
vs: None
Outcome: Cholesterol levels
효과: None
None
대상 집단: Mouse model
In Vitro
Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability …
Dose: None
vs: None
Outcome: inflammation markers
효과: None
None
대상 집단: Mice
Key Statistics
2
연구
150
참여자
↑
Positive
C
등급
Referenced Papers
Fitoterapia
2026
1 인용
Journal of the …
2026
Zhongguo zhen jiu …
2025
Nutrients
2024
47 인용
Cannabis and cannabinoid …
2024
10 인용
International journal of …
2023
9 인용
Journal of gastroenterology
2022
23 인용
NeuroImage. Clinical
2022
8 인용
Digestion
2021
29 인용
Frontiers in nutrition
2021
17 인용
Medicine
2021
Nutrition research (New …
2020
42 인용
World journal of …
2020
11 인용
Gut
2019
148 인용
Metabolomics : Official …
2019
41 인용
Pain
2019
23 인용
Scientific reports
2019
14 인용
Gut
2019
5 인용
[Not Available].
RCT
Praxis
2018
Current opinion in …
2017
71 인용
JPEN. Journal of …
2016
44 인용
Gastroenterology
2015
17 인용
Frontline gastroenterology
2012
20 인용
The American journal …
2011
48 인용
Clinical nutrition (Edinburgh, …
2011
12 인용
MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome.
Other
Gut
2010
263 인용
Clinics (Sao Paulo, …
2010
47 인용
Zhong xi yi …
2009
6 인용
Journal of clinical …
2008
73 인용
Nutrition in clinical …
2008
42 인용
Journal of proteome …
2006
80 인용
Medycyna wieku rozwojowego
2004
1 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 5-15 g/day
- ibsdsupport:
- 5 g three times daily (15 g/day total)
- postexercisegut:
- 0.25-0.9 g/kg before intense exercise
- gutbarriersupport:
- 0.5 g/kg/day (approximately 30-40 g/day for adults)
상한량: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917 | 4 weeks | Positive | 25 |
| None | -- | Mixed | 62 |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Negative | 75 |
권장 복용 시간: Between meals or before exercise; divide doses throughout the day
Safety & Side Effects
보고된 부작용
- ⚠ Mild gastrointestinal discomfort at high doses
- ⚠ Headache
- ⚠ Dizziness at very high doses
- ⚠ Potential glutamate excitotoxicity concerns in neurological conditions (theoretical)
알려진 상호작용
- ● Lactulose (glutamine may reduce the efficacy of lactulose for hepatic encephalopathy)
- ● Anti-seizure medications (glutamine converts to glutamate; theoretical concern)
- ● Chemotherapy agents (glutamine may protect cancer cells; discuss with oncologist)
일일 최대 섭취 허용량: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does L-Glutamine help with Irritable Bowel Syndrome (IBS)?
Based on 2 studies with 150 participants, there is limited but promising evidence that L-Glutamine may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is C (Some Evidence).
How much L-Glutamine should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 5-15 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of L-Glutamine?
Reported side effects may include Mild gastrointestinal discomfort at high doses, Headache, Dizziness at very high doses, Potential glutamate excitotoxicity concerns in neurological conditions (theoretical). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for L-Glutamine and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: Irritable Bowel Syndrome (IBS)
L-Glutamine 다른 건강 상태에 대한 근거
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.